Asthma | Treatment Algorithms: Claims Data Analysis | Pediatric Asthma | US | 2022

Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent exacerbations by targeting underlying pathophysiology (e.g., a LABA/ICS such as GSK’s Advair or an anti-IL-5 agent such as AstraZeneca’s Symbicort). Many pediatric asthma patients receive more than one agent for their condition. Despite the availability of multiple well-established therapies, the pediatric asthma treatment landscape has seen the approval and launch of additional agents in recent years, including novel biologics (e.g., Regeneron / Sanofi’s Dupixent) and generic versions of blockbuster inhaled drugs (e.g., albuterol sulfate and salmeterol / fluticasone propionate). These events have added more treatment options and fueled competition in this market.

Questions answered

What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric asthma patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric asthma patients?How have newer biological therapies (i.e., GSK’s Nucala, AstraZeneca’s Fasenra, Dupixent) been integrated into the treatment algorithm, and what are their sources of business?What percentage of pediatric asthma patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?What percentage of pediatric asthma patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?What are the product-level compliance and persistency rates among drug-treated patients?Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Solution enhancement

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Geography: United States

Key drugs covered: Advair, Symbicort, Dulera, Breo, Dupixent, Fasenra, Nucala, Xolair, Ventolin, ProAir, albuterol sulfate, montelukast sodium, Flovent, Qvar, Spiriva

Key analysis provided: Brand / therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flowcharts

Login to access report